Is the US Biosimilars Industry Poised for Growth?
Owners of original biomedicines are fighting tooth and nail to prevent biosimilar approvals, with patents being the principal battleground
Vela Laboratories and Evercyte Announce Cooperation to Provide Immortalized Cell Lines for Biosimilar Characterization
VelaLabs, a provider of analytical services to the global biopharmaceutical industry, and Evercyte, a producer of standardized, relevant cell systems, today (Sept. 3) announced that they have entered into a cooperation to commercialize immortalized target cells for the characterization of biosimilars in a GMP environment.